Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417902 | 1.00 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL417903 | 1.00 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2886641 | 0.96 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL29051144 | 0.92 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL29051150 | 0.92 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2443725 | 0.92 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2453027 | 0.88 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3025474 | 0.87 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL13937031 | 0.87 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2813862 | 0.85 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383647-B2 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20120035213-A1 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2392573-A1 | QUINOLINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2011-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035213-A1 | Quinoline derivative | MC1R, MCHR1, MCHR2 | RAB9A 578/4885NPC1 631/4885SMN1; SMN2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.